{"doi":"10.1016/j.intimp.2023.110966","title":"Low-dose naltrexone use for the management of post-acute sequelae of COVID-19","abstract":"The global prevalence of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) stands at approximately 43 % among individuals who have previously had acute COVID-19. In contrast, in the United States, the National Center for Health Statistics (NCHS) estimates that around 11 % of individuals who have been infected with SARS-CoV-2 go on to experience long COVID. The underlying causes of PASC remains under investigation, and there are no currently established FDA-approved therapies. One of the leading hypotheses for the cause of PASC is the persistent activation of innate immune cells with increase systemic inflammation. Naltrexone is a medication with anti-inflammatory and immunomodulatory properties that has been used in other conditions that overlap with PASC. We performed a retrospective review of a clinical cohort of 59 patients at a single academic center who received low-dose naltrexone (LDN) off-label as a potential therapeutic intervention for PASC. The use of LDN was associated with a fewer number of symptoms, improved clinical symptoms (fatigue, post-exertional malaise, unrefreshing sleep, and abnormal sleep pattern), and a better functional status. This observation warrants testing in rigorous, randomized, placebo-controlled clinical trials.","journal":"International Immunopharmacology","year":2023,"id":325941,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9557,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":51246,"name":"Lü Tian","orcid":"0000-0002-5893-0169","position":1,"is_corresponding":false},{"id":104965,"name":"Vincent C. Marconi","orcid":"0000-0001-8409-4689","position":2,"is_corresponding":false},{"id":14780,"name":"Robert W. Shafer","orcid":"0000-0003-2513-2643","position":3,"is_corresponding":false},{"id":247284,"name":"Grace A. McComsey","orcid":"0000-0003-2690-8888","position":4,"is_corresponding":false},{"id":619242,"name":"Mitchell G. Miglis","orcid":"0000-0001-8488-0313","position":5,"is_corresponding":false},{"id":663694,"name":"Philip Yang","orcid":"0000-0001-5142-1137","position":6,"is_corresponding":false},{"id":1044816,"name":"Andres Bonilla","orcid":null,"position":7,"is_corresponding":false},{"id":1044296,"name":"L. Eggert","orcid":"0000-0002-0560-0254","position":8,"is_corresponding":false},{"id":872280,"name":"Linda N. Geng","orcid":"0000-0002-9891-5705","position":9,"is_corresponding":false},{"id":264385,"name":"Hector Bonilla","orcid":"0000-0002-0513-8733","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-19T01:08:28.266998Z","pmid":"37804660","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}